Navigation Links
Piedmont Pharmaceuticals Gains FDA Approval of Animal Health Soft Chew Pain Medication
Date:6/20/2013

Greensboro, NC (PRWEB) June 20, 2013

Last week the US Food and Drug Administration’s Center for Veterinary Medicine approved the first application of Piedmont Pharmaceuticals’ invention of a canine soft chew formulation containing a veterinary medicine. This flavored soft chew formulation contains carprofen and is labeled for the relief of pain and inflammation from osteoarthritis and the control of post-operative pain in dogs. It is the first and only flavored, soft and chewable medicine in the pain category.

The soft chew formulation will provide pet owners with a convenient and friendly way to medicate dogs. According to Roland Johnson, Chairman and CEO of Piedmont Pharmaceuticals, “The veterinary pharmaceutical industry has been working on a soft chew formulation for the past two decades and we are proud, following a relatively short development timeline, to have successfully registered this highly palatable, wonderfully textured product to positively impact the medicating experience for both dogs and their owners.” In addition Johnson noted that, “this formulation has been issued multiple US patents in the past two years.”

Osteoarthritis is a problem for dogs as they get older, particularly for larger breeds. A common sign that owners will notice in their dog is difficulty climbing stairs or jumping into the back of a car. Pain is the third largest veterinary treatment category in companion animal health.

Piedmont Pharmaceuticals is a company that develops FDA and EPA regulated products for animals, emphasizing dogs and cats. In addition, their pipeline includes livestock products along with a group of technology-related human products.

Read the full story at http://www.prweb.com/releases/2013/6/prweb10854864.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1

Related biology technology :

1. Wake Forest Baptist Medical Center Unveils Historic World-Class Biotech Research & Innovation Center in Downtown Winston-Salems Growing Piedmont Triad Research Park
2. Piedmont Chemical Launches 100 Percent Renewable Polyester Polyols Leveraging Renewable Chemicals from DuPont Tate & Lyle Bio Products and Myriant Corporation
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
5. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
6. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
7. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
8. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
11. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... Clinovo , the cloud-based ... Electronic Data Capture (EDC) system ClinCaptureand its new Contract Research Organization (CRO) Partner ... Conference in San Mateo, California on February 10th and 11th. Watch 2-min ...
(Date:2/9/2016)... ... February 09, 2016 , ... PharmApprove ... for the National Organization for Rare Disorders (NORD). Dorman will lead PharmApprove efforts ... are heard throughout the drug regulatory review process. , “Adding Diane Dorman is ...
(Date:2/9/2016)... February 9, 2016 Three-Year Initiative Supports ... to Take Part in Life-Changing Camp ... designed to positively affect the lives of children born with rare ... --> SHPG ) is announcing a new initiative designed to ... well as the future of rare disease care. --> ...
(Date:2/8/2016)... Pa. , Feb. 8, 2016 Should ... standard bone cement products to prevent infection after standard ... that the experts at ECRI Institute have been fielding ... Infection or Fighting Your Bottom Line?" ... Your Bottom Line?" --> While ...
Breaking Biology Technology:
(Date:2/2/2016)... 2016 Checkpoint Inhibitors for Cancer – ... Are you interested in the future of cancer ... inhibitors. Visiongain,s report gives those predictions to 2026 ... level. Avoid falling behind in data or ... revenues those emerging cancer therapies can achieve. There ...
(Date:2/2/2016)... RESTON, Va. , Feb. 2, 2016 /PRNewswire/ ... contract award from the U.S. Army Research Office ... extend the range and sensitivity of the company,s ... DoD,s Past Accounting Mission and, more generally, defense-related ... its DNA phenotyping capabilities (predicting appearance and ancestry ...
(Date:2/1/2016)... 2016 Rising sales of consumer ... touchfree intuitive gesture control market size ... of consumer electronics coupled with new technological advancements to ... size through 2020   --> ... technological advancements to drive global touchfree intuitive gesture control ...
Breaking Biology News(10 mins):